Regarding lung cancer, four anti-PD1/PD-L1 drugs (Nivolumab, Pembrolizumab, Atezolizumab, and Durvalumab) were approved by the FDA because of their significant impact on its treatment. The gene discussed is CD274; the disease is lung carcinoma.